Current trends suggest that existing treatment and prevention options are not sufficient to stanch the AIDS epidemic. "We need innovation in HIV prevention," says Feinberg. "We must better understand people's constraints and preferences in using HIV prevention, and make sure they can access and adhere to existing methods. But we will also need new approaches that better reflect people's lives. Vaccines have proven to be the most effective tool to help control and eradicate infectious diseases."
While remarkable progress has been made, the HIV/AIDS epidemic is far from being over. While 17 million people were receiving antiretroviral treatment by the end of 2015, nearly 20 million people living with HIV worldwide still didn't have access to treatment. Ambitious targets have helped save millions of lives and reduce new annual infections by more than 30% since 2000. However, infection rates have leveled around 2 million for more than five years now despite more-than-doubled treatment rates. In 2015, new HIV infections increased for the first time in 15 years, by 5 percent, to 2.1 million globally.
Sub-Saharan Africa was home to two-thirds of the world's new HIV infections in 2015. Women there are shouldering a disproportionate share of the burden, and infection rates among that demographic as well as the large and fast-growing group of young people remain alarmingly high. Meanwhile, new HIV infections in Eastern Europe and Central Asia rose by 57 percent in 2015 alone.
A vaccine is needed to conclusively and sustainably end HIV/AIDS
Recent modeling data show that even with massively expanded use of current treatment and prevention options, hundreds of thousands of people in the low- and middle-income countries will be newly infected with HIV and die from AIDS for decades to come. The same modeling work suggests that an efficacious, well-adopted vaccine could prevent the majority of new annual HIV infections in low- and middle-income countries, averting millions of infections and savings millions of lives.
Founded in 1996, the International AIDS Vaccine Initiative is a nonprofit organization working to accelerate development of broadly effective AIDS vaccines accessible to all. IAVI works with partners in 25 countries to research, design and develop promising vaccine candidates. We collaborate with governments, partner with pharmaceutical and bio-tech companies, universities, hospitals and civil society organizations, and conduct our own research at labs in North America, Europe, Africa, and India. We also actively strengthen the expertise and infrastructure to fight HIV/AIDS in sub-Saharan Africa, the epicenter of today's epidemic. Our vision is a world without AIDS, and that world has a vaccine.
IAVI's work is made possible by generous support from many donors including: the Bill & Melinda Gates Foundation; the Ministry of Foreign Affairs of Denmark; Irish Aid; the Ministry of Finance of Japan in partnership with The World Bank; the Ministry of Foreign Affairs of the Netherlands; the Norwegian Agency for Development Cooperation (NORAD); the United Kingdom Department for International Development (DFID), and the United States Agency for International Development (USAID). The full list of IAVI donors is available at www.iavi.org.
Arne Naeveke, PhD
Tel: +1 212 847 1055
Logo - http://photos.prnewswire.com/prnh/20131210/DC30761LOGO
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/ending-aids-will-require-innovation-in-hiv-prevention--especially-a-vaccine-300281871.html
SOURCE International AIDS Vaccine Initiative